Filtered By:
Condition: Heart Disease
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 183 results found since Jan 2013.

Evaluating the efficacy and safety of percutaneous coronary intervention (PCI) versus the optimal drug therapy (ODT) for stable coronary heart disease: a systematic review and meta-analysis
DISCUSSION: Compared with ODT, PCI reduced the mortality and myocardial infarction rate of patients with CTO or severe coronary artery stenosis. However, the incidence of stroke, revascularization, and quality of life of patients were not significant different between PCI and ODT. Performance bias and detection bias should be cautioned.PMID:35572911 | PMC:PMC9096285 | DOI:10.21037/jtd-22-222
Source: Journal of Thoracic Disease - May 16, 2022 Category: Respiratory Medicine Authors: Xiaodong Qian Haoze Deng Jiamin Yuan Junting Hu Lujia Dai Tingbo Jiang Source Type: research

An Asian Perspective on Gender Differences in In-Hospital and Long-Term Outcome of Cardiac Mortality and Ischemic Stroke after Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Sex and gender-specific differences in cardiovascular disease and outcomes have been a subject of ongoing debate, as differences in clinical course, management and clinical outcomes in ischemic heart disease have been established.1 –3 While in-hospital and longer-term mortality seemed to be decreasing, it has appeared to be a less dramatic improvement in women compared to men.4-7
Source: Journal of Stroke and Cerebrovascular Diseases - November 20, 2021 Category: Neurology Authors: Jinghao Nicholas Ngiam, Elizabeth Hui-en Thong, Poay Huan Loh, Koo Hui Chan, Mark Y Chan, Chi-Hang Lee, Adrian F Low, Huay Cheem Tan, Joshua P Loh, Hui Wen Sim Source Type: research

Does Prior Stroke Predict Long-Term Recurrent Stroke After Percutaneous Coronary Intervention? Five-Year Results From a Large Cohort Study
Conclusions: Coronary heart disease patients with prior stroke who received PCI had a higher incidence of 5-year long-term adverse cardiovascular and cerebrovascular events, especially recurrent stroke. Prior stroke was a strong risk predictor of future stroke events.
Source: Frontiers in Neurology - November 2, 2021 Category: Neurology Source Type: research

Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation
CONCLUSION: After coronary stent implantation, dual therapy with a NOAC and a P2Y12 inhibitor is recommended, subsequent to triple therapy given only during the peri-interventional period.PMID:33637173 | DOI:10.3238/arztebl.m2021.0150
Source: Deutsches Arzteblatt International - February 27, 2021 Category: General Medicine Authors: Conrad Genz Ruediger C Braun-Dullaeus Source Type: research

Predictors of change in cardiovascular disease risk and events following gastric bypass: a 7-year prospective multicenter study
CONCLUSION: This study identified multiple presurgery factors that characterize patients who may have more cardiovascular benefit from RYGB, and patients who might require additional support to improve their cardiovascular health.PMID:33582036 | DOI:10.1016/j.soard.2020.12.013
Source: Surgery for Obesity and Related Diseases : official journal of the American Society for Bariatric Surgery - February 14, 2021 Category: Surgery Authors: Amanda S Hinerman Samar R El Khoudary Abdus S Wahed Anita P Courcoulas Emma J M Barinas-Mitchell Wendy C King Source Type: research

Comprehensive Outcomes Evaluation After Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short- Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-analysis of Randomized Control Trials
Abstract: Newer generation drug eluting stents (DES) and pharmacotherapy have decreased thrombotic events post-percutaneous coronary intervention (PCI). There is lack of wide-ranging safety and efficacy evaluation in both stable ischemic heart disease and acute coronary syndrome in short-term (3–6 months) versus Standard-term (12 months) dual antiplatelet therapy (DAPT). We searched electronic databases using specific terms to identify randomized control trials comparing different durations of DAPT after PCI with DES. The outcomes of interest included all-cause mortality, myocardial infarction, stent thrombosis, majo...
Source: Journal of Cardiovascular Pharmacology - November 1, 2020 Category: Cardiology Tags: Original Article Source Type: research

Influence of CYP2C19 genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease.
Authors: Yu D, Ma L, Zhou J, Li L, Yan W, Yu X Abstract The aim of the study was to compare the clinical efficacy and safety of ticagrelor and clopidogrel in patients with coronary heart disease one year after percutaneous coronary intervention (PCI), and to explore their association with the CYP2C19 gene polymorphism. A total of 971 patients with coronary heart disease who were hospitalized and underwent PCI from April 2016 to May 2017 were studied. All 971 patients were divided into three subgroups according to CYP2C19 gene types as fast metabolizing, slow metabolizing and very slow metabolizing type. Patients we...
Source: Experimental and Therapeutic Medicine - April 10, 2020 Category: General Medicine Tags: Exp Ther Med Source Type: research

Long-Term (10-Year) Outcomes of Stenting or Bypass Surgery for Acute Coronary Syndromes and Stable Ischemic Heart Disease With Unprotected Left Main Coronary Artery Disease
ConclusionsIn patients with LMCA disease, we have identified no significant interaction between the acuity of clinical indication and the relative treatment effect of PCI versus CABG on 10-year clinical outcomes.
Source: American Heart Journal - August 22, 2019 Category: Cardiology Source Type: research

Outcomes of left Main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial
ConclusionsThe acuity of presentation did not predict outcomes in patients with LMCAD undergoing revascularization, nor did it discriminate patients who derive greater event-free survival from PCI versus CABG.
Source: American Heart Journal - May 4, 2019 Category: Cardiology Source Type: research

Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research